$12.82
0.55% yesterday
Nasdaq, May 20, 10:11 pm CET
ISIN
US21900C3088
Symbol
CRMD

CorMedix Inc Stock price

$12.82
+4.68 57.49% 1M
+2.08 19.37% 6M
+4.72 58.27% YTD
+7.77 153.86% 1Y
+9.46 281.55% 3Y
+8.69 210.41% 5Y
-17.28 57.41% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.07 0.55%
ISIN
US21900C3088
Symbol
CRMD
Sector

Key metrics

Market capitalization $869.51m
Enterprise Value $792.49m
P/E (TTM) P/E ratio 56.88
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 9.60
P/S ratio (TTM) P/S ratio 10.53
P/B ratio (TTM) P/B ratio 7.56
Revenue (TTM) Revenue $82.55m
EBIT (operating result TTM) EBIT $14.47m
Free Cash Flow (TTM) Free Cash Flow $-13.63m
Cash position $77.50m
EPS (TTM) EPS $0.23
P/E forward 25.64
P/S forward 6.03
EV/Sales forward 5.50
Short interest 12.00%
Show more

Is CorMedix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

CorMedix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a CorMedix Inc forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a CorMedix Inc forecast:

Buy
100%

Financial data from CorMedix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
83 83
-
100%
- Direct Costs 3.97 3.97
309% 309%
5%
79 79
8,202% 8,202%
95%
- Selling and Administrative Expenses 57 57
34% 34%
69%
- Research and Development Expense 6.30 6.30
41% 41%
8%
15 15
128% 128%
18%
- Depreciation and Amortization 0.56 0.56
167% 167%
1%
EBIT (Operating Income) EBIT 14 14
126% 126%
18%
Net Profit 17 17
134% 134%
21%

In millions USD.

Don't miss a Thing! We will send you all news about CorMedix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CorMedix Inc Stock News

Neutral
Investors Business Daily
one day ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Neutral
GlobeNewsWire
6 days ago
BERKELEY HEIGHTS, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, will be participating in the RBC Capital Markets Global Healthcare Conference, taking place in New York on May 20-21, 2025.
Neutral
Seeking Alpha
15 days ago
CorMedix, Inc. (NASDAQ:CRMD ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Dan Ferry – LifeSci Advisors Joe Todisco – Chief Executive Officer Matt David – Executive Vice President and Chief Financial Officer Liz Hurlburt – Executive Vice President, Chief Clinical Strategy and Operations Officer Conference Call Participants Gregory Renza – RBC Capital Roana Ruiz –...
More CorMedix Inc News

Company Profile

CorMedix, Inc. operates as a pharmaceutical and medical device company. The firm seeks to license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.

Head office United States
CEO Joseph Todisco
Employees 65
Founded 2006
Website www.cormedix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today